DAA

A transient positive association between direct-acting antiviral therapy for hepatitis C infection and drug-related hospitalization among people who inject drugs: Self-controlled case-series analysis of national data

We investigated associations between outcomes and DAA treatment by comparing post-treatment to baseline periods using a within-subjects design

Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study

This study compared mortality rates for patients treated for hepatitis C in the era of direct acting antivirals with the general population

Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon-free therapies: A population-based cohort study

This study explores the impact of interferon-free therapies on hepatitis C virus related hepatocellular carcinoma at a population level.

Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs

We estimated HCV reinfection rates among PWID in Scotland pre and post-introduction of DAAs.

Reduction in the population prevalence of HCV viraemia among people who inject drugs associated with scale-up of direct-acting antiviral therapy in community drug services: real world data

We assessed the impact of rapid DAA scale‐up to PWID delivered through community services in the Tayside region of Scotland.

Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study

We examined the impact of the introduction of direct-acting antiviral (DAA) therapies on hepatitis C related decompensated cirrhosis (DC) through analysis of population-based data from Scotland.